Skip to main content
. 2022 Sep 13;3:932530. doi: 10.3389/fpain.2022.932530

Figure 4.

Figure 4

Daily systemic administration of the TLR2–TLR4 antagonist (+)-Naltrexone [(+)-NTX] reverses EAE-related pain in Sprague-Dawley (SD) rats. Sprague-Dawley (SD) rats were baselined (BL) for mechanical withdrawal thresholds via the von Frey test, followed by intradermal low-dose (0, 8, and 16 μg) myelin oligodendrocyte glycoprotein (MOG). (+)-NTX [6 mg/kg subcutaneously (SC) 3x/day] vs. saline was initiated on day 17 post-MOG, continuing through day 30 (see gray rectangle indicating span of drug delivery), and allodynia was assessed thereafter across the timecourse shown, continuing through day 30. All doses of MOG induced full mechanical allodynia by day 17, which lasted through day 29. (A) Main effects of day [F(3, 84) = 100.80; p < 0.0001], treatment [F(3, 28) = 47.51; p < 0.0001], and interaction between day and treatment [F(9, 84) = 20.89; p < 0.0001]. (B) Main effects of day [F(3, 72) = 82.07; p < 0.0001], [F(3, 24) = 34.74; p < 0.0001], and interaction between day and treatment [F(9, 72) = 17.73; p < 0.0001]. N = 8/group. Post-hocs: * indicates significant differences between 0 μg MOG-saline and each dose of MOG; # indicates significant differences between MOG-saline and MOG-(+)-NTX.